Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Has early detection improved?: Trends in localized PDAC diagnoses in the U.S. (2004-2022).

Dina Hauptschein, Paul Kang, Surabhi Amar Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16454

e16454 Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers in the United States; most...

Pembrolizumab–lenvatinib beyond immunotherapy progression in endometrial cancer: A real-world analysis.

Alberto Farolfi, Chiara Casadei, Emanuela Scarpi et al. Jun 01, 2026 pp. 5612-5612 10.1200/jco.2026.44.16_suppl.5612

5612 Background: The integration of immune checkpoint inhibitors (ICIs) into frontline therapy for advanced or recurrent e...

Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade (ICB)–based first line therapies in metastatic renal cell carcinoma (mRCC).

Rahul Winayak, Xinran Qi, Ali Moradi et al. Jun 01, 2026 pp. 4519-4519 10.1200/jco.2026.44.16_suppl.4519

4519 Background: The Clostridium butyricum -based live biotherapeutic, CBM588, dem...

Impact of endometrial cancer surgery on the development of cardiovascular risk factors in women under 51.

Calla Khilnani, Grace DiGiovanni, Guillaume Stoffels et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17645

e17645 Background: In younger patients, the rising burden of endometrial cancer (EC) intersects with cardiovascular (CV) d...

Leisure-time physical activity among US cancer survivors, 2020-2024.

Ruixuan Wang, Kathryn H. Schmitz, Anna Tanasijevic et al. Jun 01, 2026 pp. 10623-10623 10.1200/jco.2026.44.16_suppl.10623

10623 Background: Physical activity (PA) after a cancer diagnosis reduces treatment-related side effects and improves qual...

Antibody-drug conjugate adoption in triple-negative breast cancer through community-based quality improvement.

Reshma L. Mahtani, Ilona Dewald, Samuel Dooyema et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23328

e23328 Background: Community oncology settings face challenges adopting evidence-based protocols for integrating novel the...

Upfront low-dose diet-modified nilotinib versus standard imatinib in Indian patients with newly diagnosed chronic-phase chronic myeloid leukemia: The NILLOW phase II randomised trial.

Deepak Garg Jun 01, 2026 pp. 6584-6584 10.1200/jco.2026.44.16_suppl.6584

6584 Background: Upfront use of second-generation tyrosine kinase inhibitors in chronic myeloid leukemia (CML) is limited...

Incidence of early-onset colorectal cancer in the United States: A population-based analysis (2000-2019).

Tahreem Malik, Thomas Greco, Joseph Maslak Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15676

e15676 Background: The incidence of colorectal cancer (CRC) among individuals younger than 50 years has been increasing in...

Interrupting sedentary time to improve cardiometabolic health and toxicity in patients with lymphoma receiving chemotherapy: The iSTAND trial.

Rebekah Wilson, Samantha Sterghos, James Cannon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps12173

TPS12173 Background: Among lymphoma patients treated with steroids, hyperglycemia is a common side effect. Episodes of hyp...

Real-World outcome of apalutamide therapy in mHSPC patients depending on age, dose reduction, and PSA decline: Data from the German AmPel trial.

Axel Hegele, Denny Varughese, Lennart Skrobek et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17094

e17094 Background: Data from the Titan Trial (apalutamide + ADT) showed a benefit for mHSPC patients who achieved low ( &l...

Early experience with T-cell receptor cellular therapy in advanced solid malignancies: A multi-center analysis of safety and efficacy.

Neelam Singh, Zoya Peelay, Atanu Bhattacharjee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14511

e14511 Background: T-cell receptor (TCR) therapy, by targeting intracellular antigens, represents a significant expansion...

Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial—A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.

Rosa Maria Alvarez Alvarez, Nadia Hindi, Irene Carrasco-Garcia et al. Jun 01, 2026 pp. 11507-11507 10.1200/jco.2026.44.16_suppl.11507

11507 Background: Liposarcoma (LPS) and leiomyosarcoma (LMS) account for most retroperitoneal sarcomas. Despite complete r...

Multiplexed immunohistochemistry (mIHC) analysis and clinical outcomes of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in patients with refractory colorectal cancer (phase 1b/2).

Soohyeon Lee, Keun-Wook Lee, Sae-Won Han et al. Jun 01, 2026 pp. 3602-3602 10.1200/jco.2026.44.16_suppl.3602

3602 Background: Colorectal cancer (CRC) patients who are refractory or intolerant to oxaliplatin- and irinotecan-based re...

Telehealth use at the end of life among Medicare decedents with cancers.

Teresa M. Waters, Xin Hu, Haofan Yang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23120

e23120 Background: Telehealth use has surged since the COVID-19 pandemic. For individuals with cancer approaching end-of-l...

Treatment strategies and survival outcomes in hepatic epithelioid hemangioendothelioma: A systematic review.

Eric Wah Sanji, Maxime Tindong, Fomengia Joseph Nkeangu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16239

e16239 Background: The hepatic epithelioid hemangioendothelioma, or HEHE, is a very rare type of blood vessel cancer that...

A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.

Roisin Eilish O'Cearbhaill, John W. Moroney, Lainie P. Martin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5639

TPS5639 Background: REGN5668 and ubamatamab are immunoglobulin G4-based bispecific antibodies that bridge mucin 16 (MUC16)...

Machine learning–based multi-omics analysis to identify the role of MAN1C1 in pancreatic cancer and its clinical significance as a drug target.

Siyao Liu, Wenhui Lou, Yueming Zhang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16475

e16475 Background: Exploring genes related to glycosylation modification, particularly the role of MAN1C1 in PDAC, contrib...

Workforce availability for cancer surgery in rural areas: A collaboration with the American Board of Surgery (ABS).

Jennifer F. Tseng, Ryan W. Walters, Veer S. Sawhney et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13517

e13517 Background: Surgical care remains central to solid cancer treatment in adults. A shortage of surgeons, including in...

Twenty years of colon cancer epidemiology and treatment patterns in São Paulo, Brazil: A population-based analysis of observed vs. expected treatment utilization.

Laura Patton, Brooke Wilson, Haydee Cristina Verduzco-Aguirre et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13625

e13625 Background: Colon cancer disproportionately impacts survival in individuals living in low to middle-income countrie...

Financial and time toxicity among patients with cancer enrolled in pharmacotherapy clinical trials: Systematic reviews.

Ronald Chow, James Im, Camilla Zimmermann et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24053

e24053 Background: Financial and time toxicity are increasingly described as burdens of cancer care, yet their magnitude a...

Understanding circulating tumor DNA (ctDNA) test uptake among diverse cancer patients: A real-world evidence study.

Guanming Chen, Albert Lee, Juha Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23374

e23374 Background: Circulating tumor DNA (ctDNA) testing is increasingly used in oncology for clinical indications includi...

An audit of initial experience of stereotactic body radiotherapy for extracranial oligometastases.

Rohit Mahajan, Anil Goel, Sapna Marcus Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23333

e23333 Background: To retrospectively review the toxicity and early outcome data from patients who have received stereotac...

Inpatient CAR-T safety in the United States: Severe ICANS and CRS by donor source and antigen target (NIS 2022–2023).

Ashish Nepal, Suhail Sapkota, Trilok Shrivastava et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19006

e19006 Background: The field of CAR-T is rapidly expanding, with emerging allogeneic (donor-derived) platforms and multipl...

Population-level trends and geographic disparities in pancreatic cancer mortality among individuals with psychoactive substance use disorders: A retrospective analysis.

Hadia Ghazala Masood, Sarim Hassan Shahab, Irza Shaikh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22591

e22591 Background: Pancreatic cancer is a very lethal malignancy with persistently poor outcomes. Individuals with mental...

Primary breast malignancies in adolescents and young adults: The MD Anderson Cancer Center experience.

Samanta Catueno, Adrian Gutierrez, Amanda Balch et al. Jun 01, 2026 pp. 10006-10006 10.1200/jco.2026.44.16_suppl.10006

10006 Background: Primary malignancies of the breast rarely affect adolescents and are uncommon in young adults. Limited i...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page